Core Insights - Windtree Therapeutics has strengthened its cardiovascular patent estate with recent notifications of allowed patents for Istaroxime in Canada and Mexico, and a granted patent for pure SERCA2a activators in Israel [1][2][5] Patent Developments - The company now holds a total of 59 issued or allowed patents and 17 pending patents related to Istaroxime and its SERCA2a activators [1][2] - The cardiovascular patent estate includes patents for Istaroxime, dual mechanism SERCA2a activators, and pure SERCA2a activators aimed at treating heart failure, preventing arrhythmias, and addressing cardiogenic shock [2] Market Context - Heart failure affects approximately 60 million people globally, with around 20 million annual hospital admissions due to acute heart failure, including 1.5 million in the US [3] - Current treatment options for acute heart failure are limited and can lead to side effects such as arrhythmias and renal function issues [4] Product Profile - Istaroxime is a first-in-class dual-mechanism therapy designed to enhance both systolic and diastolic cardiac function, showing significant improvement in cardiac function and blood pressure without increasing heart rate or causing significant cardiac rhythm disturbances [7] - The pure SERCA2a activators are being evaluated in preclinical studies, including both oral and intravenous formulations for heart failure [8]